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Background. Underlying insulin resistance and/or obesity has clearly been implicated in the development of metabolic syndrome
in adolescents and young adults with polycystic ovarian syndrome (PCOS). It is not clear however what role hyperandrogenism
has on the development of metabolic syndrome or its role on those metabolic parameters associated with metabolic syndrome.
Methods. We studied 107 adolescent girls; 54 had PCOS according to NIH criteria. Data was obtained for systolic and diastolic
blood pressure (SBP and DBP), body mass index (BMI), total testosterone (T), luteinizing hormone (LH), follicle-stimulating
hormone (FSH), prolactin, fasting lipid proﬁle, and glucose. The PCOS group was divided initially into subgroups according
to BMI (kg/m2), then based on T (ng/dL) levels as follows: High Testosterone PCOS (HT), Intermediate Testosterone PCOS
(IT), Obese and Normal Testosterone (ONT), and lean and normal T (Control, C). t-test analysis was performed in between all
the groups. Results. There was no statistical diﬀerence between HT and IT, HT and ONT, or IT and ONT in SBP, DBP, fasting
blood glucose, lipid panel, LH, FSH, and prolactin levels. The control group had lower SBP and BMI comparing with ONT, IT,
and HT groups. There were no statistical diﬀerences found in DBP, fasting blood glucose, lipid panel, LH, FSH, or Prolactin.
Conclusion. Metabolic proﬁle in adolescent girls with PCOS is not aﬀected by either the presence of hyperandrogenism or the
degree of hyperandrogenism.
1.Introduction
Polycystic Ovarian Syndrome (PCOS) is a heterogeneous
group of conditions that include anovulation, hyperandro-
genism,andpolycysticovaries.PCOSisoftenassociatedwith
both obesity and metabolic syndrome.
The NIH-National Institute of Child Health and Human
Development Conference of PCOS originally recommended
that the major criteria for PCOS should include hyper-
androgenism and/or hyperandrogenemia, oligoovulation,
ultrasound pattern of polycystic ovaries and the exclusion
of other known disorders. A PCOS diagnosis is considered
a hyperandrogenic disorder of exclusion with an ovarian
etiology. In 2003, the Rotterdam consensus expanded the
diagnostic criteria to include at least two of the following
three features: clinical and/or biochemical hyperandro-
genism, oligoanovulation, and polycystic ovaries, excluding
any other endocrinopathies [1]. In 2006, the Androgen
Excess-PCOSsocietyrecommendedthatPCOSbedeﬁnedby
clinical and/or biochemical hyperandrogenism, with either
oligoanovulation and/or polycystic ovaries, excluding related
disorders [2].
The circulating total and free testosterone and dehy-
droepiandrosterone sulfate (DHEAS) levels are elevated in
50–75% of women with PCOS, if high quality assays are used
[3]. Androgen excess is considered by some investigators to
bethekeyfeatureofPCOS;however,only80–85%ofwomen
with clinical hyperandrogenism have PCOS [4, 5]. Despite
this evidence hyperandrogenism remains an important part
of PCOS and is included as major set of symptoms in both2 International Journal of Endocrinology
NIH and Rotterdam criteria [1]. According to the NIH
criteria PCOS aﬀects 6–10% of women of the child bearing
age [6–10]. As per the broader Rotterdam criteria even more
individuals can be classiﬁed as having PCOS [11]. Therefore
PCOS becomes one of the most common human disorders
and the single most common endocrinopathy in women of
reproductive age.
According to a common view PCOS is a multifactorial
and polygenic in nature [1, 11, 12]. Up to now multiple
studiesfailedtoidentifygenesresponsibleforPCOSandcon-
dition [12].
Metabolic syndrome is associated with development of
hyperandrogenism and PCOS. But the question still remains
unanswered as to what is primary or secondary: metabolic
syndrome or hyperandrogenism. There is an opinion and
data suggests that testosterone was signiﬁcantly related to
metabolic syndrome and its components in obese adolescent
girls[13,14].Otherdatarevealsthatinobeseadolescentgirls
PCOS does not add additional risk of further complications
of metabolic syndrome [15, 16]. PCOS adolescent girls have
been found to have increased visceral abdominal fat [16, 17],
but there was no correlation between visceral abdominal
tissue and total testosterone or free androgen index [15, 16].
There are case studies that show that low HDL cholesterol
is the criterion which best explains the high prevalence
of the metabolic syndrome in PCOS subjects which, in
turn, is inﬂuenced by hyperinsulinemia, rather than by
hyperandrogenemia [18].
In both animal and human models the associations
between serum testosterone and insulin resistance or meta-
bolic syndrome/type 2 diabetes/PCOS risk in women were
demonstrated, but their cross-sectional nature did not allow
conclusions about causality [19].
As such the aim of our study was to ﬁnd out whether
elevated testosterone level impacts the presentation of met-
abolic syndrome in obese adolescent girls.
2.MaterialsandMethods
2.1. Patients. We enrolled 107 adolescent girls from the pedi-
atric endocrinology clinics and adolescent clinic at SUNY
Downstate Medical Center. PCOS group was selected based
on NIH criteria including irregular menses and clinical
and biochemical signs of hyperandrogenism. The study was
approved by IRB of SUNY Downstate Medical Center.
2.2. Exclusion Criteria. Congenital Adrenal Hyperplasia,
Cushing’s Syndrome, severe insulin resistance, and andro-
gen-secreting tumors were excluded in all cases. Also ex-
cluded from this study were patients under treatment with
any lipid-lowering drugs, insulin sensitizers (e.g., Met-
formin), or Inositol supplements.
Thecontrolgroupwasselectedfromtheadolescentclinic
patients seen for routine health examinations. The majority
of the patients were of African American descent.
Table 1: Distribution of main metabolic parameters between
groups.
PCOS No PCOS
HT
(N = 23)
IT
(N = 31)
ONT
(N = 38)
C
(N = 15)
Age 16.6 ± 1.7 16.0 ± 1.4 15.9 ± 1.4 16.2 ± 1.9
Wt/Ht 33.4 ± 7.1 29.5 ± 6.5 33.3 ± 8 21.6 ± 2.1∗#∧
BMI 30 ± 72 9 ± 9.4 37 ± 92 4 ± 4∗#∧
SBP 120 ± 11 122 ± 12 123 ± 11.2 110 ± 9.4∗#∧
DBP 70.5 ± 8 73.5 ± 7.8 71 ± 5.2 65 ± 8
Glucose 81.6 ± 9 82.4 ±
11.3 92 ± 33 87 ± 7
HDL 50 ± 11 52.3 ±
14.3 46 ± 7.46 46 ± 9
TG 75 ± 39 74 ± 38.5 75 ± 32 75 ± 38
LH 16.2 ± 6.5 16.2 ± 6.5 10 ± 7.4 14 ± 12
Prolactin 11.1 ± 3.2 9.2 ± 4.7 9.2 ± 4.7 11 ± 4.2
∗P<0.05 between C and ONT, #P<0.05 between C and IT, ∧P<0.05
between C and HT. HT: High Testosterone; IT: Intermediate Testosterone;
O N T :O b e s ea n dN o r m a lT e s t o s t e r o n e ;C :C o n t r o l ;W t / H tw e i g h to v e r
height, BMI: Body mass index, SBP: systolic blood pressure, DBP: diastolic
blood pressure, HDL: High-density lipoprotein, TG: triglycerides, LH:
Luteinising hormone.
The patients were divided into 4 subgroups.
(1) High Testosterone (HT): patients that met the NIH
and Rotterdam Criteria for PCOS and had Total
Testosterone > 90ng/dL;
(2) Intermediate Testosterone (IT): patients that met the
NIH and Rotterdam Criteria for PCOS and had Total
Testosterone in range 51–90ng/dL;
(3) Obese and Normal Testosterone (ONT): patients
that did not fulﬁll the NIH and Rotterdam Criteria
for PCOS and had BMI > 95th percentile, total
testosterone < 50ng/dL;
(4) Controls (c) Patients that did not fulﬁll the NIH
and Rotterdam Criteria for PCOS and had BMI <
95th percentile, Total Testosterone < 50 and regular
periods, and did not meet any of the exclusion
criteria.
The group of 54 girls who had PCOS according to NIH crite-
ria including irregular period or amenorrhea and increased
level of testosterone was subdivided into 2 subgroups with
(a) 23 patients with high level of testosterone (T) and (b) 31
patients with intermediate level of testosterone (T).
As a control we assigned 15 patients who had normal
BMI and normal level of testosterone.
The ONT group consisted of 38 patients who had ele-
vated BMI and normal testosterone.
Characteristics of the patients are detailed in Table 1.
2.3. Measurements Methods. Data was obtained for blood
pressure, BMI, testosterone, LH, FSH, prolactin, fasting
lipid proﬁle, and glucose. BMI was calculated as weightInternational Journal of Endocrinology 3
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Figure 1: Systolic Blood Pressure—distribution among the groups.
HT: High Testosterone, IT: Intermediate Testosterone; ONT: Obese
Normal Testosterone; C: Controls.
(kg)/(height (cm))2 and BMI above 95th percentile accord-
ing to the CDC [20], BMI charts was deﬁned as obese.
Testosterone was determined by chemiluminescent im-
munoassay methodology; high testosterone was deﬁned
as testosterone above 90ng/dL and high intermediate as
between 51 and 90ng/dL.
2.4. Statistical Analyses. Two-sample t-test assuming une-
qual variances analysis was performed to compare the means
of the studied parameter between the 4 groups.
Multivariate logistic regression analysis was done for
testosterone levels and LH, FSH, prolactin, lipid proﬁle, fast-
ing glucose, SBP, DBP, and BMI. For the statistical analysis
we used the SPSS 19.0 software.
3. Results
There was no statistical diﬀerence between the high testos-
terone group HT and the other groups IT and ONT in
SBP, DBP, fasting blood glucose, lipid panel, LH, FSH, and
prolactin.
Furthermore our analyses did not yield any statistically
signiﬁcant diﬀerence between the intermediate testosterone
group IT and ONT in any of the studied parameters
(Table 1).
The control group had lower SBP and BMI comparing
with the other groups but no statistical diﬀerence was found
in DBP, fasting blood glucose, lipid panel, LH, FSH, or
prolactin (Figure 1). The regression analysis did not yield
any correlation between the testosterone levels and any of the
other parameters.
The regressions were run both for the entire population
studied and for each separate subgroup.
Table 2: Correlations of BMI with the studied parameters.
rP value
SBP 0.5 <0.001
DBP 0.23 <0.001
Total cholesterol 0.25 <0.01
HDL 0.27 <0.01
LDL 0.33 <0.01
LH 0.19 0.03
Triglycerides 0.06 0.56
FSH 0.06 0.49
Prolactin 0.08 0.35
BMI: Body mass index, SBP: systolic blood pressure, DBP: diastolic blood
pressure, HDL: High-density lipoprotein, LDL: Low-density lipoprotein,
LH: Luteinising hormone, FSH: Follicle-stimulating hormone.
BMI had statistically signiﬁcant correlations with SBP,
DBP, cholesterol proﬁle, and LH but no correlation was seen
for triglycerides, FSH, and prolactin (Table 2).
4. Discussion
Upon review of the literature, several studies suggest that
PCOS and high testosterone is an additional risk and is sig-
niﬁcantly related to metabolic syndrome and its sequelae in
obese adolescent girls [21–25]. PCOS in adolescent patients
has been found to have increased visceral abdominal fat
[17], but there was no correlation between visceral abdom-
inal tissue and total testosterone or free androgen index
[15]. An elevated risk proﬁle for cardiovascular morbidity
was demonstrated in PCOS patients, mainly attributed to
increases in type 2 diabetes, dyslipidemia, and hypertension
[18, 26, 27] which might constitute a cofounder when
studying the correlation between hyperandrogenism and the
risk of metabolic syndrome in PCOS.
However, contrary with such studies [28, 29], we found
that there were no signiﬁcant diﬀerences in the relationship
between the degree of hyperandrogenism and the metabolic
parameters associated with metabolic syndrome. The level
or degree of hyperandrogenism did not alter the metabolic
parameters in our study group.
While it is known that PCOS is signiﬁcantly more
prevalent among obese patients [30] and altered metabolic
parameters are directly associated to degrees of BMI [31],
there is still no consensus as to the question of what is
primary or secondary metabolic syndrome or hyperandro-
genism. PCOS is polygenic condition and may be inﬂuenced
byenvironmentalfactorslikedietandlifestyle.Inﬁrst-degree
female relatives of PCOS patients, it has been documented to
be an increase in adrenal androgens and insulin resistance
in these girls thus suggesting a genetic component. However,
to date, there is no clearly deﬁned genetic etiology that is
associated with PCOS and it is not clear whether hyperan-
drogenism is involved in the pathogenesis of this disorder.
We may speculate that increased rate of metabolic syn-
dromeamongobesegirlwithPCOSmaybeconfoundedwith
obesity rather than hyperandrogenism. Another reason for4 International Journal of Endocrinology
lack of correlation between PCOS and metabolic syndrome
in adolescent girls may be that patients should be exposed to
androgens longer to develop metabolic abnormalities in the
adult age.
It is important for further studies to investigate the
eﬀects of prolonged exposure to high circulating androgens
mainly in lean PCOS patients and the progression of this
phenotype to metabolic syndrome. It is our belief that there
may be an associated pathophysiological link with obesity,
particularly visceral adiposity, and related adipose tissue
factors, coagulation abnormalities, or insulin resistance [16,
19, 32] that may independently increase cardiovascular risk
rather than a direct association of hyperandrogenism with
metabolic syndrome morbidities.
Our study was limited by its small sample size. There
can be limitations arising from the sample collection method
or the chemiluminescent immunoassay method used to
determine testosterone levels. However, this is unlikely to
alter the main conclusions.
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